Supplement Spotlight: Don’t Choke on the Obvious

September 3, 2019

Every so often the FDA does or says something so biased against the dietary supplement industry that it is difficult to understand how we are supposed to consider ourselves as working together in any form of real partnership. The Annals of Internal Medicine recently published an article ( 20 Aug 2019) entitled Swallowing Problems and Dietary Supplements: Data From U.S. Food and drug Administration Adverse Event Reports, 2006-2015. All of the authors are from either the FDA Office in College Park Maryland or the Center For Disease Control in Atlanta, GA. The objective of the article was stated as ‘identifying and characterizing dietary supplement associated swallowing problems in relation to pill size’ by using 10 years of data from adverse event reports submitted to the FDA Center for Food Safety and Applied Nutrition and Adverse Event Reporting System. The background for the article states that FDA has provided voluntary guidance to pharma regarding the size of generic drug tablets and capsules. The FDA recommends that capsules or tablets should not exceed 17mm and must not exceed 22mm. “Currently”, the authors note, “similar guidelines do not exist for dietary supplements; however, these products have been implicated in swallowing problems, particularly among adults aged 65 years and older.”

Other important points from this report to pay attention:

  • 6% of the reported swallowing problems involved females.
  • Of the 64.5% of the reports that included age data, 76.8% of the reported swallowing problems involved adults 65 years or older.
  • Ten dietary supplements accounted for 76.4% of swallowing problems and involved products with a mean pill length, width and height of 19.3mm, 9.8mm, 7.8mm respectively, all measurements in excess of the FDA guidelines for generic drugs.
  • The incidence for reporting of swallowing complications was 12.7 times higher with the mean measurements reported above.
  • Seven of the ten products accounting for 64.5% of all swallowing problems were multivitamins marketed to older adults.
  • A single multivitamin product marketed to older women was involved in 40.6% of all the swallowing problem reports.

This brief research report implies that because the FDA regulates and guides the prescription market the problem of choking is not relevant. A 2016 report on Emergency Department visits for outpatient adverse drug events contradicts this implication. Moreover as reported in Injury Facts 2017, choking is the fourth leading cause of unintentional injury and over 56% of people who died from choking in 2015 were older than 74.

With that said, there are some key learnings from this report that the dietary supplement industry as responsible industry leaders should take into account. Primarily, the size guidelines set forth by the FDA for the generic drug industry listed above could and should be applied to supplements. Here are some simple safety takeaways the dietary supplement industry can easily implement to improve the safety profile of the products.

  • Follow the guideline of keeping capsules or tablets below 17mm in length.
  • Special consideration in this regard should be taken into consideration when marketing to the elderly and/or females.
  • Alternative delivery formats (i.e., gummies, chews, liquid) may also combat swallowability issues

In total, despite author bias and focus, this report serves as a wake-up call for our industry. We have an opportunity to reinforce the overall safety profile of dietary supplements in comparison to pharmaceutical adverse events by taking the steps above.


Punzalan C, Budnitz DS, Chirtel SJ, Geller AI, Jones OE, Mozersky RP, et al. Swallowing Problems and Dietary Supplements: Data From U.S. Food and Drug Administration Adverse Event Reports, 2006–2015. Ann Intern Med. [Epub ahead of print 20 August 2019] doi: 10.7326/M19-0947

Andrew I. Geller, M.D., Nadine Shehab, Pharm.D., M.P.H., Nina J. Weidle, et al. Emergency Department Visits for Adverse Events Related to Dietary Supplements N Engl J Med 2015; 373:1531-1540 DOI: 10.1056/NEJMsa1504267

Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014. JAMA. 2016;316(20):2115–2125. doi:10.1001/jama.2016.16201

Unlock the Power of Transparency: Schedule a Meeting Now

Ready to Illuminate Your Path?
Partner with Trust Transparency Today.

Get inTouch

Lori Diez

Lori Diez combines compassion and excellence to lead organizations to their next level. A small-town Texas childhood taught her the value of hard work and relationships, which she uses to foster teamwork that brings results that have transformed cultures and programs to their highest potential. Her successful career in pharmaceutical and nutraceutical sales leadership and event hosting has prepared her to deliver results as the COO of TrustTransparency, where she uses her industry knowledge to ensure that the company’s operations run smoothly as they support nutraceutical companies in their mission to help others. Lori’s passion for charity reflects her belief that individuals working together can change the world, no matter how small their contribution to the effort. This year, she looks forward to continuing over a decade of service at the Houston Livestock Show And Rodeo, where she will be the Chairman of the Livestock Committee.

Conference Handouts

Conference Handouts

CoQ10 Statin Associated Myaglia Meta Study Barry Tan 0618 Case Study

CoQ10 Statin Associated Myaglia Meta Study Barry Tan 0618 (1)

Statin Q10 Effect Case Study

Statin Q10 Effect Case Study

Schedule Consultation with Trust Transparency

Glynnda Steinford

Glynnda Steinford, Trust Transparency Consulting’s Director of Customer Relations, brings over four decades of healthcare experience to her vital role in client engagement and relationship building. Her diverse background spans from administering medical groups to impactful stints in pharmaceutical and nutraceutical sales, all underlined by her degree in Healthcare Administration.

At the heart of Glynnda’s work is her talent for nurturing long-term connections, a skill she leverages to enhance client experiences and partnerships within the consultancy. Beyond her professional commitments, she enjoys life’s simple pleasures, whether it’s her love for cats and cooking or her ventures into golf, always prioritizing cherished moments with family and friends. Her personal interests echo the dedication and warmth she extends in her professional network, making her an invaluable asset to the team.

Caiti Dowden

Caiti Dowden stands as a crucial pillar at Trust Transparency Consulting, bringing invaluable insight and expertise to her role as Senior Executive Assistant’ since her start in 2018. With an academic background from Sam Houston University and a career shift from education to the nutraceutical sphere in 2010, Caiti has cultivated a sharp acumen for dissecting industry trends and bolstering strategic decision-making.

Her transition from Data Analyst reflects her growth and deep understanding of the business landscape. Caiti’s commitment goes beyond professional excellence; she thrives on balance, drawing from her rich life outside of work to enhance her organizational contributions. Whether it’s family time, volunteering, or rooting for Houston’s sports teams, she believes in embracing experiences to fuel her professional creativity and insight.

In her current role, Caiti’s dedication to dynamic business analysis and operational support proves her to be an irreplaceable asset to our team, embodying the synergy of personal enrichment and professional success.

Pam Hilpert

Pam Hilpert, Chief of Staff at Trust Transparency Consulting, has been instrumental in the firm since its inception, leveraging her 17 years of accounting experience, including a significant tenure in the nutrition sector. Her collaboration with Scott Steinford spans various successful ventures, emphasizing her integral role in the company’s financial and strategic initiatives.

An alumnus of Sam Houston State University, Pam holds degrees in both Business Administration and Accounting, as well as an MBA, adding academic heft to her practical industry insights. Beyond her professional prowess, Pam is passionate about family, enjoys live music, delves into quilting, and volunteers at her church, reflecting her well-rounded life.

Her multifaceted expertise and longstanding dedication make Pam a cornerstone of Trust Transparency Consulting’s operational strength and team unity.

Scott Steinford

Scott Steinford, a trailblazer in strategic leadership, boasts a certified M&A background, having navigated companies from their genesis to industry prominence. His brainchild, Trust Transparency Consulting, born in 2007, stands as a testament to his dedication to ethical business practices and strategic foresight, offering industry stakeholders invaluable guidance.

Beyond founding and steering companies, Scott has enriched the business landscape with his insightful keynotes and prolific written contributions, emphasizing his commitment to elevating industry standards. His executive tenure shines in roles as CEO or President of for-profits like ZMC-USA and Doctor’s Best, extending to significant contributions in non-profit sectors.

Notably, Scott’s influence is a driving force in the CoQ10 market, where his leadership has significantly bolstered the ingredient’s global presence. His roles in various capacities, including as a New Hope Ambassador, keep the community informed, providing in-depth industry reports and insights.

An active advocate within professional associations and an Editorial Advisor for leading industry publications, Scott’s expertise is both recognized and sought after. With academic roots in Pre-Law and a Master’s in Law, his journey transcends textbooks, embodying real-world business acumen and transformative leadership.

Scott Steinford merges visionary entrepreneurship with principled leadership, creating a legacy of innovation, growth, and unwavering commitment to industry excellence.